Hemostatic response to postprandial lipemia before and after exercise training.
Chronic hypertriglyceridemia is thought to be atherogenic and is associated with an elevated thrombotic potential, both of which may be improved with aerobic exercise training. Eight subjects were tested for aerobic capacity, body composition, and postprandial lipemia (PPL), followed by 6 mo of exercise training and final testing. Blood samples were obtained for measurement of free fatty acid (FFA), triglycerides (TG), insulin (Ins), and glucose (Glu). Hemostatic variables including factor VII activity (FVIIa), tissue factor pathway inhibitor-factor Xa complex (TFPI/Xa), and plasminogen activator inhibitor-1 (PAI-1) antigen/activity as well as leukocyte tumor necrosis factor-alpha (TNF-alpha) gene expression were determined among four subjects. We found that the exercise training was of sufficient intensity to increase aerobic capacity (P < 0.0001) and improve body composition (P = 0.04). There were no differences between tests among PPL responses of FFA, TG, Ins, or Glu; however, the mean TG response and fat oxidation rate improved. PAI-1 antigen/activity, FVIIa, TFPI/Xa, and TNF-alpha gene expression were all improved after exercise training after adjusting for confounders. We conclude that aerobic exercise training reduces the potential for coagulation, improves fibrinolytic potential, and reduces leukocyte TNF-alpha gene expression after the ingestion of a high-fat meal.
Paton
Chad M
CM
Department of Kinesiology, University of Maryland, College Park, USA. chad.paton@bcw.edu
Brandauer
Josef
J
Weiss
Edward P
EP
Brown
Michael D
MD
Ivey
F M
FM
Roth
Stephen M
SM
Hagberg
James M
JM
D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D004041:Dietary Fats / Q000494:pharmacology; D015444:Exercise / Q000502:physiology*; D005167:Factor VII / Q000032:analysis / Q000235:genetics / Q000502:physiology; D015951:Factor Xa / Q000032:analysis / Q000235:genetics / Q000502:physiology; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects / Q000502:physiology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D006487:Hemostasis / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood / Q000235:genetics / Q000502:physiology; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000235:genetics / Q000502:physiology; D019518:Postprandial Period / Q000502:physiology*; D012333:RNA, Messenger / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000235:genetics / Q000502:physiology
D004041:Dietary Fats; D008055:Lipids; D008074:Lipoproteins; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; C051928:lipoprotein-associated coagulation inhibitor; D005167:Factor VII; D015951:Factor Xa